Plasma C3d Levels and Ischemic Heart Disease in Type II Diabetes

OBJECTIVE To test the hypothesis that the complement system may be activated in patients with type II diabetes and CAD.

RESEARCH DESIGN AND METHODS The plasma C3d concentration was measured in 106 type II diabetic patients and 25 nondiabetic control subjects. The patient group was subdivided according to AER, and the groups were adjusted for age, sex, and known duration of diabetes. For the assignment to a given subgroup, normoalbuminuria was defined as AER < 15 μm/min, microalbuminuria as AER 16–250 μg/min, and macroalbuminuria as AER > 250 μg/min. The presence or absence of coronary disease was assessed through clinical examination, ECG, and coronary angiography. An RIA system was used for measurement of urinary albumin levels, and the plasma C3d concentrations were measured by ELISA.

RESULTS Within each of the AER-defined subgroups, the plasma C3d levels were significantly higher in patients with IHD than in those without. Thus, in the normoalbuminuric group, plasma C3d levels were 16.3 AU/ml (95% CI 13.9–19) in patients with IHD vs. 11.6 AU/ml (95% CI 10.5–12.7) in those without (P < 0.001). The corresponding data for the microalbuminuric and macroalbuminuric groups were 21.8 (95% CI 18.1–26.3) vs. 13.6 (95% CI 12.3–15.1) and 31.6 (95% CI 24.9–40) vs. 17.5 (13.6–22.6) AU/ml (P < 0.01), respectively. Patients with IHD also had significantly higher plasma C3d levels than normal control subjects, regardless of AER subgroup. A multiple logistic regression analysis demonstrated an association between the plasma C3d concentration and IHD and AER.

CONCLUSIONS Activation of the complement system may play a role in the development of macrovascular disease in type II diabetes.